Utility:
| SSc sera was tested for anti-BICD2 using a paramagnetic bead immunoassay and the association between anti-BICD2 and demographic and clinical parameters as well as other SSc-related autoantibodies was evaluated. 25.7% (116/451) were anti-BICD2 positive, of which 19.0% had single specificity anti-BICD2 and 81.0% had other autoantibodies, notably anti-CENP (83/94; 88.3%). Compared to anti-BICD2 negative subjects (335/451), single specificity anti-BICD2 subjects were more likely to have an inflammatory myopathy (IM; 31.8% vs. 9.6%, p = .004) and interstitial lung disease (ILD; 52.4% vs. 29.0%, p = .024). It was observed that BICD2 was te second most common autoantibody identified in the SSc cohort. |